S&P 500 rides Tesla rally to fresh record ahead of Fed meeting
Investing.com - CLSA upgraded Fisher & Paykel Healthcare (ASX:FPH) (OTC:FSPKF) from Hold to Outperform on Tuesday, raising its price target to NZD37.80 from NZD34.50.
The upgrade comes as CLSA recognizes Fisher & Paykel Healthcare’s "quality business with a solid history of product innovation" that supports the firm’s positive outlook for the company.
CLSA noted the company is successfully driving adoption of its OptiFlow system outside intensive care units while also benefiting from high-quality product launches in its obstructive sleep apnea (OSA) portfolio.
The research firm believes the company’s quality justifies a premium valuation despite tariff headwinds, describing its current valuation as "attractive" in the context of broader healthcare market uncertainty.
CLSA also mentioned that rising COVID-19 cases may support sales growth in the second half of fiscal year 2026, though the firm remains cautious about these emerging trends.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.